Patients eager for ‘longer acting Botox’ says rival toxin developeron 26th April 2018
A botulinum toxin developer has said that customers are heavily anticipating the release of its as-yet unapproved product, which the company has termed a ‘longer acting Botox’.
Talking to Bloomberg News, Revance Therapeutics CEO Dan Browne said, however, that the product will likely not be launched for another two years.
The product candidate, known as RT002, is currently in late-stage testing for its first indication, which is expected to be for glabellar lines.
Results from an open-label safety study of the product have not yet been released, but if the product meets its approval timeline, a launch could be on the cards (in the US at least) in 2020.
Revance is targeting FDA approval to show RT002, a botulinum toxin similar to Allergan’s Botox, lasts up to six months, compared to a three- to four-month label claim for Botox.
The company’s chief operating officer, Abhay Joshi, says Revance has stated data proving the six-month duration claim.
What’s more, Dan Browne says the company sees RT002 as a ‘performance product’ and intends to seek ‘premium pricing’ for it, and will also be targeting development of the product for the treatment of migraines.
Allergan’s Botox achieved global net revenues of $3.2 billion for Allergan in 2017, an increase of 13.7% over the previous year.
Ipsen Pharma’s Azzalure (named Dysport overseas) generated net revenues of €382.2 million worldwide in 2017, up from €284.7 million in 2016.
In the UK, Azzalure is licensed to Galderma.